Invivogen
Menu

Anti-hTNF-α-hIgA2

Product Unit size Cat. code Docs. Qty. Price

Anti-hTNF-α-hIgA2

Human TNF-α (Adalimumab) antibody - Human IgA2

Show product

100 µg

3 x 100 µg

htnfa-mab7
+-
$109
  • About
  • Specifications
  • Contents
  • Details
  • Related products

Human IgA2 monoclonal antibody (mAb) against human TNF-α

Neutralizing monoclonal antibody against human TNF-α
Neutralizing monoclonal antibody against human TNF-α

Anti-hTNF-α-hIgA2 is a neutralizing monoclonal antibody (mAb) featuring the constant region of the human IgA2 (hIgA2) isotype and the variable region of adalimumab, a fully human therapeutic mAb that targets human tumor necrosis factor-alpha (hTNF-α). The variable region of adalimumab blocks the interaction of soluble and membrane-bound TNF-α with its receptors TFNR1 and TNFR2, thereby downregulating the inflammatory responses [1, 2]. 

Anti-hTNF-α-hIgA2 was generated by recombinant DNA technology. It is produced in CHO cells and purified by affinity chromatography with peptide M. The neutralizing activity of Anti-hTNF-α-hIgA2 was determined using recombinant human TNF-α and HEK-Blue™ TNF-α cells. TNF-α is a pleiotropic cytokine that notably induces NF-κB-mediated production of pro-inflammatory cytokines [1, 2].

More details More details

 

Human IgA2 Isotype

The human IgA2 isotype is highly resistant to enzymatic degradation by bacterial proteases, due to a short hinge region. Human IgA2 displays low potency for Fc-mediated antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP), and it does not mediate complement-dependent cytotoxicity (CDC). 

Review Learn more about antibody isotype effector functions by reading our flyer on Clinically relevant monoclonal antibodies.

 

References:

1. Steeland S., et al. 2018. A new venue of TNF targeting. Int. J. Mol. Sci. 19:1442.
2. Shealy D.J. & Visvanathan S. 2008. Anti-TNF antibodies: lessons from the past, roadmap for the future. Therapeutic Antibodies (book). 101-129.

Figures

Evaluation of hTNF-α inhibition
Evaluation of hTNF-α inhibition

Increasing concentrations of Anti-hTNF-α-IgA2 were incubated for 30 minutes with the recombinant cytokine hTNF-α (30 pg/ml) prior to the addition of HEK-Blue™ TNF-α cells. After overnight incubation, SEAP activity in the cell culture supernatant was assessed using QUANTI-Blue™ Solution. Data are shown in percentage (%) of neutralization.

Back to the top

Specifications

Specificity: Human TNF-α (hTNF-α)
Clonality: Monoclonal antibody
Isotype: Human IgA2​, kappa
Control:  Anti-β-Gal-hIgA2
Source: Chinese hamster ovary (CHO) cells
Purification: Affinity chromatography with peptide M
Formulation: 0.2 µm filtered solution in TRIS buffer with glycine, saccharose, and stabilizing agents
Tested application: Blocking & Neutralization of hTNF-α signaling

Quality control:

  • Human IgA2 isotype has been confirmed by ELISA.
  • The neutralization of hTNF-α signaling pathway has been confirmed using cellular assays with the HEK-Blue™ TNF-α cells.
  • The absence of bacterial contamination (e.g. lipoproteins and endotoxins) has been confirmed using HEK-Blue™ TLR2 and HEK-Blue™ TLR4 cells.
Back to the top

Contents

Anti-hTNF-α-hIgA2 purified monoclonal antibody is provided azide-free and lyophilized. It is available in two quantities:

  • htnfa-mab7: 100 µg
  • htnfa-mab7-3: 3 x 100 µg 

room temperature Product is shipped at room temperature.

store Upon receipt, store lyophilized antibody at -20°C.

Back to the top

Details

Tumor necrosis factor-alpha (TNF-α) is a pleiotropic cytokine involved in necrotic and apoptotic cell death, cellular differentiation, inflammation, and regulation of immune cell activity [1]. TNF-α is mainly produced by activated monocytes, macrophages, and T cells. It is first synthesized as a membrane-bound molecule that forms a compact homotrimer through non-covalent interactions. The trimeric membrane-bound form is cleaved by tumor necrosis factor-alpha converting enzyme (TACE) releasing the soluble trimer [2]. Both the membrane-bound and soluble TNF-α bind homotrimeric transmembrane receptors, TNFR1 or TNFR2, triggering signaling pathways that involve TRADD, TRAF2, and RIP, and leading to the activation of NF-κB and MAPK pathways. Importantly, membrane-bound TNF can also mediate a reverse "outside-to-inside" signaling, although this mechanism remains to be fully elucidated [2].

 

References:

1. Steeland S., et al. 2018. A new venue of TNF targeting. Int. J. Mol. Sci. 19:1442.
2. Shealy D.J. & Visvanathan S. 2008. Anti-TNF antibodies: lessons from the past, roadmap for the future. Therapeutic Antibodies (book). 101-129.

Back to the top
Customer Service
& Technical Support
Shopping cart is empty